These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 10686688)

  • 1. [Management of acute coronary syndrome. New pharmacologic approaches].
    Galvani M; Nicolini FA; Ferrini D; Ottani F
    G Ital Cardiol; 1999; 29 Suppl 4():23-7. PubMed ID: 10686688
    [No Abstract]   [Full Text] [Related]  

  • 2. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).
    Budaj A; Brieger D; Steg PG; Goodman SG; Dabbous OH; Fox KA; Avezum A; Cannon CP; Mazurek T; Flather MD; Van De Werf F;
    Am Heart J; 2003 Dec; 146(6):999-1006. PubMed ID: 14660991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-fractionated heparin versus low molecular weight heparin in acute coronary syndromes].
    González Pacheco H
    Arch Cardiol Mex; 2001; 71 Suppl 1():S63-8. PubMed ID: 11565348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anti-thrombins and low molecular weight heparins for acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 1999 Jun; 11 Suppl A():2A-6A. PubMed ID: 10745604
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
    Shimpi RA
    J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term subcutaneous and oral anticoagulants after acute coronary syndromes.
    Verheugt FW
    Rev Port Cardiol; 2003; 22(7-8):1011-5. PubMed ID: 14587169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful management of acute portal vein thrombosis by low molecular weight heparin and oral anticoagulation.
    Hegenbarth K; Fickert P; Aschauer M; Horina JH; Stauber RE; Trauner M
    Am J Gastroenterol; 2002 Jun; 97(6):1567-8. PubMed ID: 12094892
    [No Abstract]   [Full Text] [Related]  

  • 8. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on.
    Antman EM
    Am Heart J; 2003 Aug; 146(2):191-3. PubMed ID: 12891179
    [No Abstract]   [Full Text] [Related]  

  • 10. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation?
    Farquhar D
    CMAJ; 2001 Feb; 164(3):396. PubMed ID: 11232150
    [No Abstract]   [Full Text] [Related]  

  • 12. A new form of heparin is changing treatment of thrombotic disorders.
    Capriotti T
    Medsurg Nurs; 1998 Apr; 7(2):106-9, 98. PubMed ID: 9727125
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacologic therapy of acute coronary syndromes].
    Holm F; Aschermann M
    Cas Lek Cesk; 2003 Aug; 142(8):456-9. PubMed ID: 14626558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 16. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of thrombosis during pregnancy.
    Inbal A
    Isr Med Assoc J; 2002 Oct; 4(10):813-4. PubMed ID: 12389348
    [No Abstract]   [Full Text] [Related]  

  • 18. Preventing subacute stent thrombosis--is there a role for heparin-coated stents?
    Carrozza JP
    J Invasive Cardiol; 2003 Aug; 15(8):442-3. PubMed ID: 12890873
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
    Fitchett D; Goodman SG; Gupta M; Langer A
    Can J Cardiol; 2002 Nov; 18(11):1179-90. PubMed ID: 12464982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging antithrombotic treatments for acute coronary syndromes.
    Golino P; Ragni M; Cirillo P; Buono C; Piro O; Chiariello M
    Cardiologia; 1999 Nov; 44(11):969-80. PubMed ID: 10686772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.